New research published in MDPI’s Journal of Clinical Medicine found that mild #COVID causes stiffer and more dysfunctional arteries that could lead to #heart disease. Read about the findings in The Independent: independent.co.uk/news/health/sc…

Our co-founder, @PorrelloER, recently presented a seminar at reNEW, about the impact that cardiac maturation can have on disease modeling, drug discovery and regenerative medicine. Dive into his team’s latest research published in Cell Reports: cell.com/cell-reports/f…

A new study published in Cell Reports may have identified a solution to the life-threatening #arrhythmias caused by attempts to repair a damaged #heart with cell transplants. More about the incredible discovery via Mark Johnson The Washington Post: washingtonpost.com/science/2023/0… CC: ISCRM at UW

A study in JAMA found 12 key symptoms to reliably classify someone with long COVID. With some studies linking COVID to higher cardiovascular risk, understanding the disease better helps scientists address heart health. Via Brenda Goodman CNN: cnn.com/2023/05/25/hea…

#FDA approves first-ever anti-inflammatory drug addressing #cardiovascular risks. Previously, colchicine was used to treat gout + pericarditis. This now lower dosage is suitable for long-term use in people w/ atherosclerotic #heartdisease. Via Medscape: medscape.com/viewarticle/99…

Research presented at this year’s American Diabetes Association meeting found that bempedoic acid can be taken as a statin alternative to reduce the risk of major #cardiovascular events. More via NBC News: nbcnews.com/health/heart-h…

The U.S. FDA has approved the first drug to enter clinical trials based on efficacy data from #organoids - a breakthrough for rare disease research and treatment potential! #biotech More about the approval in BioWorld: bioworld.com/articles/52051…

A new global study published in NEJM found that statins can reduce the risk of #cardiovascular disease in people living with #HIV. The findings can change how doctors treat HIV+ patients with cardiovascular risks. Read more via Deborah J. Balthazar STAT: statnews.com/2023/07/23/sta…

The $60M research collab from Verve Therapeutics + Eli Lilly and Company, plus a new agreement between Alexion + @Pfizer, points to a promising future for #CVD-related #genomic medicine research. Learn more about Verve: ir.vervetx.com/news-releases/… And about Alexion: astrazeneca.com/media-centre/p…

The #RNAi-#cardiovascular scientific community has recently seen the announcement of two impressive collabs: Alnylam Pharmaceuticals-Roche and Ionis-Novartis. Each uses RNAi technology to treat CVD and related risks. Alnylam: investors.alnylam.com/press-release?… Ionis: fiercebiotech.com/biotech/novart…

A Novo Nordisk trial found #Wegovy can reduce the risk of #cardiovascular events by 20% in non-diabetic adults. The study could improve #insurance coverage for the drug once further peer-reviewed + published in a medical journal. Via Meg Tirrell CNN: cnn.com/2023/08/08/hea…

Did you miss our CEO’s guest appearance on Bioverge podcast last week? He spoke to host Neil Littman about the future of #cardiovascular therapeutics, the #techbio vs #biotech debate, the culture at Dynomics, and more! Check it out: soundcloud.com/user-770548556…

Now 3 years post-pandemic, scientists can better see how #COVID19 impacts our #hearthealth 🩺 Their leading theory? The virus stimulates widespread inflammation, increasing the risk of #heartattacks and #strokes. More via Dana Smith The New York Times: nytimes.com/2023/09/07/wel…

In May, the World Health Organization (WHO) released new guidance to reduce the use of #artificialsweeteners due to their link to increased #cardiovascular disease + type 2 diabetes. A recent article in NEJM rounds up several studies explaining the impact of non-sugar sweeteners: nejm.org/doi/full/10.10…

In recognition of #WorldHeartDay today, we’re taking it back to last month when our CEO, Drew Titmarsh, spoke to host Neil Littman on the Bioverge podcast. Check out the full episode: youtube.com/watch?v=UIEiM2…

Tech is a game-changer when it comes to healthcare. Last week, Anumana | AI in Cardiology | ECG-AI + Mayo Clinic received U.S. FDA clearance for their AI model that can identify signs of low ejection fraction (LEF) in ECGs. Learn more via Michael Walter Cardiovascular Business: cardiovascularbusiness.com/topics/clinica…

Last week, a deal was struck between Eli Lilly and Company and Beam Therapeutics. Lilly will pay $200M for Beam’s stake in Verve Therapeutics, a gene-editing company developing therapeutics to address cardiovascular disease. More via Matthew Herper STAT: statnews.com/2023/10/31/eli…

Biotech gene therapy shop, LEXEO Therapeutics recently announced and closed a $100M IPO. The company will use the funds to scale its main therapeutics, including its Alzheimer’s candidate being assessed for arrhythmogenic cardiomyopathy. More BioSpace: biospace.com/article/lexeo-…

In vivo base editing in humans may actually work, according to the latest data released by Verve Therapeutics. But, after identifying potential safety concerns, investors aren’t totally convinced. Read more about the latest Verve data in FierceBiotech: fiercebiotech.com/biotech/verve-…

Research in NEJM + Journal of Clinical Investigation from Penn Medicine provides insight into peripartum cardiomyopathy + dilated cardiomyopathy, rare heart conditions. Advancing such research leads to necessary progress where knowledge gaps exist. Via Medical Xpress: medicalxpress.com/news/2024-01-i…